Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Illumina reported a solid first quarter of fiscal 2026 and increased its full-year outlook. Q1 2026 revenue was $1.09 billion, up 4.8% from Q1 2025, with GAAP operating margin improving to 19.2% and non-GAAP operating margin to 21.9%. GAAP diluted EPS rose to $0.87 from $0.82, while non-GAAP diluted EPS increased to $1.15 from $0.97.
Free cash flow was $251 million, up from $208 million, and cash flow from operations reached $289 million. For fiscal 2026, Illumina now guides to $4.52–$4.62 billion in revenue and non-GAAP EPS of $5.15–$5.30. The board also authorized a new share repurchase program of up to $1.5 billion, on top of $314 million remaining under a prior $1.5 billion authorization.
Illumina Inc ownership filing reports that Vanguard Capital Management beneficially owned 7,939,213 shares of Illumina common stock, representing 5.19% of the class as of 03/31/2026. The filing shows sole voting power for 1,344,377 shares and sole dispositive power for 7,939,213 shares. The report is signed on 04/30/2026 by Ashley Grim.
Illumina is asking stockholders to approve nine director nominees, ratify Ernst & Young as auditor, and support an advisory vote on executive pay at its fully virtual annual meeting on May 21, 2026. The company highlights 2025 revenue of $4.34B, flat year over year, with 2% ex-China growth and modest gains in core sequencing consumables.
Non-GAAP operating margin improved to 23.1% from 21.3%, while non-GAAP diluted EPS rose 16% to $4.84. Illumina generated $1,079M in operating cash flow, $931M in free cash flow, and returned about $740M to stockholders via share repurchases, while emphasizing strong independent board oversight and detailed governance, risk, and compensation practices.
ILLUMINA, INC. director Scott B. Ullem acquired additional company stock as part of his board compensation. On March 31, 2026, he received 190 shares of common stock valued at $131.5473 per share, issued in lieu of his first quarter 2026 cash retainer fees. Following this award, he directly holds 8,791 shares of Illumina common stock. According to the footnote, Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock, with the number of shares based on the volume weighted average closing price during the completed quarter. This is a compensation-related grant rather than an open-market purchase.
Meister Keith A. reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director Keith A. Meister received 161 shares of common stock as a stock-based retainer on March 31, 2026. He elected to take 100% of his 2026 board and committee cash retainer fees in Illumina stock, with the share amount based on the volume weighted average closing price for the completed quarter of $131.5473 per share.
Following this grant, he holds 4,566 shares directly and reports 3,829,508 shares held indirectly for the accounts of certain Corvex Funds for which Corvex Management LP acts as investment adviser.
Illumina, Inc. announced upcoming changes to its Board of Directors, with three current members planning to retire at the 2026 annual meeting of stockholders.
Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire effective May 21, 2026, and the company states their retirements are not due to any dispute or disagreement with the company or its Board.
The Board has nominated David P. King, a former CEO and Executive Chairman of Laboratory Corporation of America with extensive healthcare and life sciences board experience, to stand for election as a director at the 2026 annual meeting.
Illumina Inc: The Vanguard Group filed an amendment to its Schedule 13G disclosing zero shares of Illumina common stock beneficially owned following an internal realignment effective January 12, 2026. The filing states Vanguard subsidiaries that formerly reported with The Vanguard Group will now report separately in reliance on SEC Release No. 34-39538.
Illumina, Inc. SVP and Chief Technology Officer Steven Barnard reported equity awards in the form of restricted stock units and performance stock units. He acquired 7,603 shares of common stock as restricted stock units and 8,871 performance stock units in each of two separate awards.
According to the terms, 25% of the restricted stock units vest on each of February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, as long as he continues as a service provider. One performance stock unit award will pay out from 0% to 250% of 8,871 shares based on the company’s three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028, with vesting on December 31, 2028. The other performance stock unit award will pay out from 0% to 250% of 8,871 shares based on relative total shareholder return for the fiscal year ending December 31, 2028, subject to continued service.